India Multiplex Assay Market Forecast 2024-2032

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $1,100	142 Pages	Inkwood Research	March, 2024	INKR18647241

Best Price Guarantee
Price	from $1,100
Length	142 Pages
Publisher	Inkwood Research
Published Date	March, 2024
SKU	INKR18647241

India Multiplex Assay Market Forecast 2024-2032

KEY FINDINGS

The India multiplex assay market growth is anticipated to progress at a CAGR of 9.58% during the forecast period, 2024-2032. The market growth is attributed to the intensified demand for advanced diagnostic solutions capable of detecting multiple biomarkers simultaneously. This is due to the rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders.

MARKET INSIGHTS

In India, the India Against Cancer initiative was launched by the National Institute of Cancer Prevention and Research (NICPR) in collaboration with medical professionals and researchers. The primary objective of this initiative is to disseminate information on prevalent cancers, emphasizing awareness, prevention, and treatment. Among Indian women, breast cancer stands out as the most common form of cancer, constituting over 25% of all female cancer cases, with a five-year survival rate of 66.4%. Additionally, cervical cancer presents a significant concern, with a five-year survival rate of 51.7%.

India's pharmaceutical sector has a rich history of reverse engineering, demonstrating its capacity to manufacture and distribute generic versions of pharmaceutical products globally. Following the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, Indian companies have redirected their research and development efforts towards innovative drug delivery systems and discovery research.

Furthermore, there are notable shifts in regulations concerning animal testing across Asia, with India implementing stringent measures in this domain. Notably, India has recently prohibited the testing of cosmetics on animals. These regulatory changes are expected to lead to the replacement of animal testing practices with in vitro methods, which offer enhanced sensitivity, accuracy, safety, ease of execution, and cost-effectiveness. Such factors are projected to drive the India multiplex assay market growth.

COMPETITIVE INSIGHTS

Some of the key companies in the market are Qiagen NV, Illumina Inc, Siemens Healthineers AG, etc.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

1. Research Scope & Methodology: 1.1. Study Objectives; 1.2. Methodology; 1.3. Assumptions & Limitations
2. Executive Summary: 2.1. Market Size & Estimates; 2.2. Country Snapshot; 2.3. Country Analysis; 2.4. Scope Of Study; 2.5. Crisis Scenario Analysis; 2.6. Major Market Findings; 2.6.1. Software And Services Sector Emerges As The Rapidly Expanding Product & Service Segment; 2.6.2. Protein-based Multiplex Assay Is The Highest Revenue-generating Type; 2.6.3. Research & Development Applications Dominate Market Share; 2.6.4. Multiplex Pcr Technology Demonstrates Faster Growth; 2.6.5. Pharmaceutical And Biotechnology Companies Are Major Users Of Multiplex Assays
3. Market Dynamics: 3.1. Key Drivers; 3.1.1. Escalating Incidence Of Chronic Diseases; 3.1.2. Growing Preference For Multiplex Assays Over Conventional Approaches; 3.1.3. Increasing Acceptance Of Personalized Medicine; 3.2. Key Restraints; 3.2.1. Overcoming The Difficulty Of Establishing Sufficient Assay Range; 3.2.2. Challenges Associated With Cross-reactivity And Assay Interference; 3.2.3. Shortage Of Skilled Professionals
4. Key Analytics: 4.1. Key Market Trends; 4.1.1. Rising Drug Discovery Endeavors; 4.1.2. Progress In Assay Platform Technology; 4.1.3. Rapid Expansion Of Companion Diagnostics; 4.2. Pestle Analysis; 4.2.1. Political; 4.2.2. Economical; 4.2.3. Social; 4.2.4. Technological; 4.2.5. Legal; 4.2.6. Environmental; 4.3. Porter’s Five Forces Analysis; 4.3.1. Buyers Power; 4.3.2. Suppliers Power; 4.3.3. Substitution; 4.3.4. New Entrants; 4.3.5. Industry Rivalry; 4.4. Market Concentration Analysis; 4.5. Key Buying Criteria; 4.5.1. Coverage Of Analytes; 4.5.2. Rapidity; 4.5.3. Ability To Multiplex; 4.5.4. User-friendliness; 4.5.5. Automation Potential; 4.6. Value Chain Analysis; 4.6.1. Research And Development (R&D); 4.6.2. Manufacturing And Production; 4.6.3. Distribution And Supply Chain; 4.6.4. Clinical Application And Data Analysis; 4.6.5. Market Research And Commercialization
5. Market By Product And Service: 5.1. Reagents And Consumables; 5.1.1. Market Forecast Figure; 5.1.2. Segment Analysis; 5.2. Instruments And Accessories; 5.2.1. Market Forecast Figure; 5.2.2. Segment Analysis; 5.3. Software And Services; 5.3.1. Market Forecast Figure; 5.3.2. Segment Analysis
6. Market By Type: 6.1. Protein-based Multiplex Assay; 6.1.1. Market Forecast Figure; 6.1.2. Segment Analysis; 6.2. Nucleic Acid-based Multiplex Assay; 6.2.1. Market Forecast Figure; 6.2.2. Segment Analysis; 6.3. Other Types; 6.3.1. Market Forecast Figure; 6.3.2. Segment Analysis
7. Market By Application: 7.1. Research And Development; 7.1.1. Market Forecast Figure; 7.1.2. Segment Analysis; 7.2. Clinical Diagnostics; 7.2.1. Market Forecast Figure; 7.2.2. Segment Analysis; 7.3. Companion Diagnostics; 7.3.1. Market Forecast Figure; 7.3.2. Segment Analysis
8. Market By Technology: 8.1. Multiplex Protein Microarray; 8.1.1. Market Forecast Figure; 8.1.2. Segment Analysis; 8.2. Multiplex Pcr; 8.2.1. Market Forecast Figure; 8.2.2. Segment Analysis; 8.3. Other Technologies; 8.3.1. Market Forecast Figure; 8.3.2. Segment Analysis
9. Market By End-user: 9.1. Pharmaceutical & Biotechnology Companies; 9.1.1. Market Forecast Figure; 9.1.2. Segment Analysis; 9.2. Research Institutes; 9.2.1. Market Forecast Figure; 9.2.2. Segment Analysis; 9.3. Clinical Laboratories; 9.3.1. Market Forecast Figure; 9.3.2. Segment Analysis; 9.4. Hospitals; 9.4.1. Market Forecast Figure; 9.4.2. Segment Analysis
10. Competitive Landscape: 10.1. Key Strategic Developments; 10.1.1. Mergers & Acquisitions; 10.1.2. Product Launches & Developments; 10.1.3. Partnerships & Agreements; 10.1.4. Business Expansions & Divestitures; 10.2. Company Profiles; 10.2.1. Agilent Technologies Inc; 10.2.1.1. Company Overview; 10.2.1.2. Product Portfolio; 10.2.1.3. Strengths & Challenges; 10.2.2. Becton, Dickinson And Company (Bd); 10.2.2.1. Company Overview; 10.2.2.2. Product Portfolio; 10.2.2.3. Strengths & Challenges; 10.2.3. Bio-rad Laboratories Inc; 10.2.3.1. Company Overview; 10.2.3.2. Product Portfolio; 10.2.3.3. Strengths & Challenges; 10.2.4. F. Hoffmann-la Roche Ltd; 10.2.4.1. Company Overview; 10.2.4.2. Product Portfolio; 10.2.4.3. Strengths & Challenges; 10.2.5. Illumina Inc; 10.2.5.1. Company Overview; 10.2.5.2. Product Portfolio; 10.2.5.3. Strengths & Challenges; 10.2.6. Qiagen Nv; 10.2.6.1. Company Overview; 10.2.6.2. Product Portfolio; 10.2.6.3. Strengths & Challenges; 10.2.7. Siemens Healthineers Ag; 10.2.7.1. Company Overview; 10.2.7.2. Product Portfolio; 10.2.7.3. Strengths & Challenges; 10.2.8. Thermo Fisher Scientific Inc; 10.2.8.1. Company Overview; 10.2.8.2. Product Portfolio; 10.2.8.3. Strengths & Challenges